6 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
and CKD EMPA-REG ... + T2DM; first renal ... outcomes in HFrEF on GDMT ... visualabstract #table ... #CVD #CKD
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... -4 inhibitors SGLT2 ... Improved outcomes in CKD ... #table #comparison
Summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents

#Diabetes #Diabetic #Medications #Pharmacology #Dosing
recommendations in renal ... Diabetes #Diabetic #Medications ... Dosing #Dosing #Renal ... #Impairment #CKD ... #Table #GFR #Hypoglycemics
Adjusted Pain Medication Dosing based on GFR

#Renal #Dosing #Pain #Pharmacology #Opiates #CKD #Gabapentin #Table
Adjusted Pain Medication ... based on GFR #Renal ... Pharmacology #Opiates #CKD ... #Gabapentin #Table
Guideline-Directed Medical Therapy (GDMT) in HFrEF and CKD

 • Class I pillars of HFrEF GDMT across
Medical Therapy (GDMT ... ) in HFrEF and CKD ... diuretics, MRA, SGLT2i ... Chronotropes • Medications ... #CKD #HFrEF #management
Causes of Secondary Hypertension - Workup and Differential Diagnosis
Approach (when evaluation should be done):
1. Severe or
with previously stable ... eg, presence of renal ... Renal parenchymal ... disease: CKD, acute ... Differential #Diagnosis #indications